Glycomine Funds Phase IIb Rare Disease Trial With $115m Series C

Drug Developer Focused On Glycosylation Disorders

 
• By Mandy Jackson
  
Glycomine raises $115m in venture capital funding (Shutterstock)

More from Financing

More from Rare Diseases